Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lexaria Bioscience Corp.LEXX · Entity 7641 | Secretary | July 29, 2025 | July 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lexaria Bioscience Corp.
Report date July 29, 2025 · Filed July 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| common sharesSEC Table I · non-derivative | Direct | 750 |
Reported balance
After 2025-07-29 transaction · row 1
1 source rowRow 1 · 2025-07-29 · Purchase · Acquired 750 · Balance 750 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2026-04-26 | Direct | 12,500 |
Reported balance
Holding disclosure · report date 2025-07-29 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 12,500 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2026-06-08 | Direct | 17,500 |
Reported balance
Holding disclosure · report date 2025-07-29 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 17,500 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2026-09-01 | Direct | 27,500 |
Reported balance
Holding disclosure · report date 2025-07-29 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 27,500 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.91 · Expires 2027-08-29 | Direct | 40,000 |
Reported balance
Holding disclosure · report date 2025-07-29 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 40,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2028-10-26 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2025-07-29 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 50,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.36 · Expires 2029-04-26 | Direct | 60,000 |
Reported balance
Holding disclosure · report date 2025-07-29 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 60,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2030-05-15 | Direct | 75,000 |
Reported balance
Holding disclosure · report date 2025-07-29 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 75,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2025 Filed Jul 30, 2025 11:23 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | Purchasecommon shares | 750 | $0.91 | $682.50 |
DisclosureSEC source: 0001348362-25-000013 · primary_doc.xml · nonDerivative · entry 1 Carle Vanessa · CIK 0001855763 · Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750 Read SEC document |
| May 15, 2025 Filed May 16, 2025 17:27 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 15,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001348362-25-000009 · primary_doc.xml · derivative · entry 7 Carle Vanessa · CIK 0001855763 · Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 15,000 shares Expires 2030-05-15 Read SEC document |
| July 31, 2024 Filed Aug 1, 2024 12:25 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | Salecommon shares | 2,567 | $4.00 | $10,268.00 |
DisclosureSEC source: 0001855763-24-000012 · primary_doc.xml · nonDerivative · entry 2 Carle Vanessa · CIK 0001855763 · Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 14, 2024 Filed May 15, 2024 17:37 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | Exercise / conversionStock Options · Derivative | 2,500 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001855763-24-000011 · primary_doc.xml · derivative · entry 10 Carle Vanessa · CIK 0001855763 · Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,067 Underlying: Common Shares · 2,500 shares Expires 2028-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2024 Filed May 15, 2024 17:37 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | Exercise / conversioncommon shares | 2,500 | $1.15 | $2,875.00 |
DisclosureSEC source: 0001855763-24-000011 · primary_doc.xml · nonDerivative · entry 2 Carle Vanessa · CIK 0001855763 · Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2024 Filed May 10, 2024 17:24 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 10,000 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001855763-24-000010 · primary_doc.xml · derivative · entry 8 Carle Vanessa · CIK 0001855763 · Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,567 Underlying: Common Shares · 10,000 shares Expires 2029-04-26 Read SEC document |
| October 26, 2023 Filed Nov 1, 2023 13:45 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 12,500 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001855763-23-000009 · primary_doc.xml · derivative · entry 7 Carle Vanessa · CIK 0001855763 · Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,567 Underlying: Common Shares · 12,500 shares Expires 2028-10-26 Read SEC document |
| August 29, 2022 Filed Aug 29, 2022 17:32 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 12,500 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001855763-22-000010 · primary_doc.xml · derivative · entry 6 Carle Vanessa · CIK 0001855763 · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,067 Underlying: Common Shares · 12,500 shares Expires 2027-08-29 Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 13:04 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 10,000 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0001855763-21-000022 · primary_doc.xml · derivative · entry 5 Carle Vanessa · CIK 0001855763 · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,567 Underlying: Common Shares · 10,000 shares Expires 2026-09-01 Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 11:15 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 5,000 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001855763-21-000010 · primary_doc.xml · derivative · entry 4 Carle Vanessa · CIK 0001855763 · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,567 Underlying: Common Shares · 5,000 shares Expires 2026-06-08 Read SEC document |
| May 07, 2021 Filed Jun 9, 2021 11:07 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | OtherStock Options · Derivative | 5,000 | $0.00 Strike: $9.60 | $0.00 |
DisclosureSEC source: 0001855763-21-000009 · primary_doc.xml · derivative · entry 5 Carle Vanessa · CIK 0001855763 · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,567 Underlying: Common Shares · 5,000 shares Expires 2025-04-23 F1 · kind: Cancellation of Options Read SEC document |
| April 26, 2021 Filed Apr 27, 2021 16:31 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 12,500 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0001855763-21-000003 · primary_doc.xml · derivative · entry 4 Carle Vanessa · CIK 0001855763 · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,567 Underlying: Common Shares · 12,500 shares Expires 2026-04-26 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.